ClinicalTrials.gg
RecruitingNCT06710353Updated Apr 23, 2025

The Effect of Preoperative Albumin Administration on Postoperative Acute Kidney Injury in Pediatric Patients With Hypoalbuminemia Undergoing Cardiac Surgery

An interventional study of Albumin solution and Crystalloid solutions in Acute Kidney Injury and Pediatric Cardiac Surgery, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged Up to 7 Years. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
Up to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Acute Kidney Injury by Seoul National University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Acute Kidney Injury · Seoul National University Hospital.

Planned enrollment
6th of 11
190 · median 190
Started
2025
the only one that year
No phase
9 of 18
2 open now
Registered
17th of 18
by date

Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 17th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 18 studies in Acute Kidney Injury by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: Up to 7 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Acute Kidney Injury by Seoul National University Hospital, or all of them as a file.
02

Study summary

The study aims to evaluate whether preoperative albumin supplementation in pediatric patients with hypoalbuminemia undergoing cardiac surgery can reduce inflammatory responses and prevent acute kidney injury (AKI) following cardiopulmonary bypass.

03

Conditions studied

  • Acute Kidney Injury
  • Pediatric Cardiac Surgery

Browse trials for

04

Who can participate

Ages eligible
Up to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients under 7 years of age undergoing cardiac surgery with cardiopulmonary bypass
  • Preoperative serum albumin level of 4.0 g/dL or lower

Exclusion criteria

Exclusion Criteria:

  • abnormal preoperative creatinine level
  • history of dialysis
  • liver dysfunction
  • diabetes
  • history of to albumin
  • coagulation disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Albumin group

    A 20% albumin solution is administered over a period of one hour, starting at the time of anesthesia induction.

  • Placebo comparator
    Control group

    The same volume of crystalloid solution as the administered albumin is infused.

Interventions

  • DrugAlbuminsStudies of AlbuminsAlbumins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A 20% albumin solution is administered over one hour starting from the induction of anesthesia, using the following formula: (4.0-preoperative serum albumin (g/dL))×plasma volume (kg×0.65-0.8 dL)

  • The same volume of crystalloid solution as the administered albumin is infused.

06

What researchers measure

Primary outcomes

  1. incidence of acute kidney injury (AKI)

    The difference in the incidence of acute kidney injury (AKI) between groups, as measured by the KDIGO criteria

    Time frame: assessed up to postoperative day 7

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 35 months is above that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Nov 29, 2024
StartActual
Jan 9, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710353
Responsible party
Ji-Hyun Lee (Associate Professor, Seoul National University Hospital) — Principal investigator
First posted
Nov 29, 2024
Start date
Jan 9, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 23, 2025

Study contacts

Ji-Hyun Lee
Contact
muslab6@snu.ac.kr
82-2-2072-3661

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion